Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

t and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.  A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 9488233.  The webcast and telephone replay will be available through September 29, 2011.  

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Forward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different fro
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 StemGenex® , the ... the US aimed at improving the lives of patients ... study for Parkinson’s disease. StemGenex believes that a ... therapy are paramount when providing care to patients with ... stem cell therapy accessible to the millions of individuals ...
(Date:7/23/2014)... 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that the underwriters of its common ... purchase an additional 420,000 shares of common stock ... share, less underwriting discounts and commissions, in connection ... 2,800,000 shares of common stock, bringing the expected ...
(Date:7/23/2014)... , July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: ... that it is filing for two medical marijuana dispensary locations ... are in addition to the Clark County, Nevada ... special use permit, as previously announced.  GrowBLOX Sciences, ... be submitting two new applications for dispensaries in the ...
(Date:7/23/2014)... With the ability to record continuously at over ... 15 minutes, Fastec Imaging has brought the same ease-of-use of ... “Finally, a high speed camera that can be used as ... lives.” proclaims Matt Kearney, VP of Sales for Fastec Imaging. ... and simplify the traditionally complicated workflow of a high speed ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3
... /PRNewswire-FirstCall/ - On August 20, 2008,Oncothyreon Inc. (Nasdaq: ... a,letter from The Nasdaq Stock Market indicating that (i) ... on The NASDAQ Global Market,because it did not meet ... other things, that the market value of,its common stock ...
... with international ... and technology companies, TORONTO, Sept. 17 Aurillion, a ... Moreno as its vice president of sales and marketing. In ... grow the company,s business throughout the Americas, Europe,and Asia. He ...
... 17 Sigma-Aldrich Corporation,(Nasdaq: SIAL ) will be ... Wednesday, September 24th at 8:30 AM ET at the ... via live audio broadcast over the,Internet available at ... this file. For the webcast on, http://ir.sigmaaldrich.com users ...
Cached Biology Technology:Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards 2Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards 3Guillermo Moreno Named Aurillion's Vice President of Sales and Marketing 2
(Date:7/23/2014)... news release is available in German . ... and stability to cells, drive metabolic processes and transmit ... complex three-dimensional shapes. Scientists at the Max Planck Institute ... proteins can be constructed of similar amino acid chains ... that the proteins that exist today arose from common ...
(Date:7/23/2014)... BioCatch, the global leader in ... has been named in Gartner,s Market Guide for Online ... well-known Magic Quadrant for Web Fraud Detection. ... several vendors to deliver passive biometric analysis and predicted, ... feature of at least 30% of one-stop fraud detection ...
(Date:7/23/2014)... clinical use of induced pluripotent stem cell (iPSC) ... hindered by the risk of dysregulated cell growth, ... use etoposide treatment to halt teratoma formation in ... acute myocardial infarction, is demonstrated in an article ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
Breaking Biology News(10 mins):Protein evolution follows a modular principle 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... January 2014 Scientists from the Montreal Neurological ... two genes linked to hereditary Parkinson,s disease are ... The protective mechanism, which is reported in T ... arise from oxidative stress from mitochondria., "PINK1 and ...
... 21, JoVE, the Journal of Visualized Experiments , ... explored one of the most intriguing research questions facing ... protocol, titled Conducting Miller-Urey Experiments, is comprised of a ... Dr. Stanley Miller and Dr. Harold Urey in 1953. ...
... viral pathogen that typically infects plants has been found ... Researchers working in the U.S. and Beijing, China report ... journal of the American Society for Microbiology. The ... "resulted in the serendipitous detection of Tobacco Ringspot Virus, ...
Cached Biology News:Quality control of mitochondria as a defense against disease 2A 21st century adaptation of the Miller-Urey origin of life experiments 2Pathogenic plant virus jumps to honeybees 2
... Roches RTS AviTag E. coli Biotinylation Kit, Linear ... 100 E. coli expression kits. (Cat. No. 3 ... reagents to rapidly generate linear expression constructs by ... based on a combination of T7 RNA polymerase ...
... (GR) Competitor Assay Kits are ideal for ... The PolarScreen GR Competitor Assay Kits contain ... and one of the following proprietary fluorescent ... GS Red (red assay kit), or GS ...
... E. coli Biotinylation Kit, Plasmid is designed for ... coli expression kits. (Cat. No. 3 186 148, ... provides vectors for the easy introduction of a ... protein can be enzymatically mono-biotinylated by E. coli ...
... Exiqons LNA technology enables sensitive, fast ... on intact chromosomes. Short hybridisation ... fixed cells and chromosome spreads Multiplex ... Pre-validated probes Probes available ...
Biology Products: